Nektar Therapeutics (NASDAQ:NKTR) shares were down 6.3% on Monday . The company traded as low as $32.16 and last traded at $32.61. Approximately 1,619,989 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 1,732,413 shares. The stock had previously closed at $34.79.
A number of research analysts recently weighed in on NKTR shares. Mizuho reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Leerink Swann started coverage on shares of Nektar Therapeutics in a research report on Friday, March 15th. They issued a “market perform” rating for the company. HC Wainwright reissued a “hold” rating and issued a $47.00 price objective on shares of Nektar Therapeutics in a research report on Monday, March 4th. Piper Jaffray Companies set a $100.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, ValuEngine downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $69.73.
The stock has a market cap of $5.68 billion, a P/E ratio of 8.97 and a beta of 2.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The company had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter last year, the company posted ($0.60) EPS. On average, equities analysts anticipate that Nektar Therapeutics will post -3.05 earnings per share for the current year.
In other news, COO John Nicholson sold 3,822 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $42.39, for a total transaction of $162,014.58. Following the completion of the sale, the chief operating officer now owns 170,655 shares in the company, valued at approximately $7,234,065.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Maninder Hora sold 2,386 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $101,142.54. Following the sale, the senior vice president now owns 99,374 shares of the company’s stock, valued at approximately $4,212,463.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 162,705 shares of company stock valued at $6,872,756. 4.31% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in Nektar Therapeutics by 4.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 224,471 shares of the biopharmaceutical company’s stock worth $13,683,000 after purchasing an additional 9,196 shares in the last quarter. Renaissance Technologies LLC raised its stake in Nektar Therapeutics by 138.7% in the 3rd quarter. Renaissance Technologies LLC now owns 68,848 shares of the biopharmaceutical company’s stock worth $4,197,000 after purchasing an additional 40,000 shares in the last quarter. Vanguard Group Inc raised its stake in Nektar Therapeutics by 3.6% in the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after purchasing an additional 660,907 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Nektar Therapeutics by 6.0% in the 4th quarter. State of Alaska Department of Revenue now owns 48,377 shares of the biopharmaceutical company’s stock worth $1,589,000 after purchasing an additional 2,731 shares in the last quarter. Finally, QUANTRES ASSET MANAGEMENT Ltd raised its stake in Nektar Therapeutics by 35.7% in the 4th quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 17,500 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 4,600 shares in the last quarter. Institutional investors own 94.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) Trading Down 6.3%” was reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2019/05/16/nektar-therapeutics-nktr-trading-down-6-3.html.
Nektar Therapeutics Company Profile (NASDAQ:NKTR)
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.